Goy, A., Sinha, R., Williams, M. E., Kalayoglu Besisik, S., Drach, J., Ramchandren, R., . . . Witzig, T. E. (2013). Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study. J Clin Oncol.
Chicago-tyylinen lähdeviittausGoy, Andre, et al. "Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study." J Clin Oncol 2013.
MLA-viiteGoy, Andre, et al. "Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study." J Clin Oncol 2013.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.